MannKind Corporation (MNKD) ended last trading session with a change of -5.57 percent. It trades at an average volume of 5.14M shares versus 5.85M shares recorded at the end of last trading session. The share price of $0.63 is at a distance of 53.71 percent from its 52-week low and down -71.87 percent versus its peak. The company has a market cap of $297.43M and currently has 471.96M shares outstanding. The share price is currently -5.58 percent versus its SMA20, 7.31 percent versus its SMA50, and -31.34 percent versus its SMA200. The stock has a weekly performance of -1.02 percent and is -1.02 percent year-to-date as of the recent close.
On Jan. 09, 2017 MannKind Corporation (MNKD) confirmed that it received $30.6 million from Sanofi on January 6, 2017, representing the balance of the accelerated insulin “put” option previously exercised by MannKind. This payment was made pursuant to a previously disclosed agreement reached with Sanofi on November 9, 2016.
MannKind Corporation (MNKD) (MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind.
Array BioPharma Inc. (ARRY) recently recorded 5.15 percent change and currently at $9.4 is 294.96 percent away from its 52-week low and down 1.62 percent versus its peak. It has a past 5-day performance of 6.94 percent and trades at an average volume of 3.79M shares. The stock has a 1-month performance of 7.92 percent and is 6.94 percent year-to-date as of the recent close. There were about 166.29M shares outstanding which made its market cap $1.56B. The share price is currently 7.7 percent versus its SMA20, 21.22 percent versus its SMA50, and 93.89 percent versus its SMA200.
On Jan. 3, 2017 Array BioPharma Inc. (ARRY) announced that its Chief Executive Officer, Ron Squarer, will speak at the Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11, 2017 at 8:30 a.m. Pacific Time in Westin St. Francis Hotel, San Francisco. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.